Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL164600 | 0.69 | PARP1 (0.42) | PARP1GAAMAPT | |
| Water SCHEMBL15092682 | 0.67 | PARP1 (0.41) | PARP1GAAMAPT | |
| Bromide SCHEMBL166261 | 0.67 | PARP1 (0.41) | PARP1GAAMAPT | |
| Hydrochloric Acid SCHEMBL163943 | 0.67 | PARP1 (0.46) | PARP1GAAMAPT | |
| Hydrochloric Acid SCHEMBL166212 | 0.65 | PARP1 (0.44) | PARP1GAAMAPT | |
| SCHEMBL20924 | 0.65 | PARP1 (0.35) | PARP1GAAMAPT | |
| SCHEMBL33554 | 0.64 | — | — | |
| SCHEMBL3767165 | 0.64 | MAPT (0.53) | PARP1GAAMAPT | |
| SCHEMBL29398195 | 0.64 | — | — | |
| SCHEMBL29375766 | 0.64 | MAPT (0.53) | PARP1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024003558-A1 | PRODRUGS OF LYSYL OXIDASE INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-01-04 | — | — | WO | disclosed |
| WO-2024003557-A1 | SULFOXIMINES AS INHIBITORS OF LYSYL OXIDASE | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-01-04 | — | — | WO | disclosed |
| EP-4277631-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | Liverpool School of Tropical Medicine (GB) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023285788-A1 | SULFUR COMPOUNDS AND PROCESSES AND INTERMEDIATES USEFUL IN THE PREPARATION THEREOF | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022152918-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2022-07-21 | — | — | WO | disclosed |
| WO-2021084265-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021084264-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-06 | — | — | WO | disclosed |
| EP-3802492-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | Oxford University Innovation Limited (GB) | 2021-04-14 | — | — | EP | disclosed |
| EP-3743421-A1 | COMPOUNDS | Oxford University Innovation Limited (GB) | 2020-12-02 | — | — | EP | disclosed |
| EP-3743414-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | Oxford University Innovation Limited (GB) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019145718-A1 | COMPOUNDS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019145719-A1 | INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-08-01 | — | — | WO | disclosed |
| WO-2018234780-A1 | METHODS AND MEDICAL USES | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2018-12-27 | — | — | WO | disclosed |
| WO-2018234778-A1 | METHODS AND MEDICAL USES | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2018-12-27 | — | — | WO | disclosed |
| WO-2018167276-A1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS | Argonaut Therapeutics Limited (GB) | 2018-09-20 | — | — | WO | disclosed |
| WO-2018167269-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | Argonaut Therapeutics Limited (GB) | 2018-09-20 | — | — | WO | disclosed |
| WO-2018087527-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-17 | — | — | WO | disclosed |
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | PARP1 3423/4885GAA 1942/4885MAPT 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.